Special Issue "Molecular Biomarkers for Cancer Targeted Therapeutics"
A special issue of Diagnostics (ISSN 2075-4418).
Deadline for manuscript submissions: closed (15 November 2012)
Dr. Jianli Dong
Department of Pathology, Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, 5.202 John Sealy Annex, 301 University Boulevard Galveston, TX 77555, USA
Interests: biomarkers in clinical application; molecular diagnostics; signaling pathway in cancer biology
Advances in cancer genetics and molecular techniques are providing increased opportunities for molecular diagnostics in cancer. Cancer molecular tests typically analyze nucleic acid-based biomarkers and can be classified based on clinical application as diagnostic, prognostic, and predictive. Cancer diagnostic tests are used for cancer screening, diagnosis, subtyping, and staging; cancer prognostic tests reveal the nature course of cancer, disease outcome and recurrence following treatment; whereas cancer predictive tests provide information on the likely response of a patient to a drug or therapy. Often, a single molecular oncology test can find its application in more than one categories based on the clinical scenario. Molecular tests are expected to have ever-increasing impact on clinical management of cancer patients. For example, molecular diagnostics are developed to select patients who will benefit to a targeted therapeutics, to monitor the development of treatment resistance, to assess recurrence following treatment, to modify the dose of a therapeutic, and to identify the pharmacogenetic risk of adverse drug reactions. This way, correct treatment is determined per patient, non-effective treatments can be spared, and side-effects avoided, thus leading to personalized and precision cancer management.
Dr. Jianli Dong
- cancer molecular diagnostics
- nucleic acid
- companion molecular diagnostics
- molecular targeted therapy
Article: Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma
Diagnostics 2013, 3(1), 13-32; doi:10.3390/diagnostics3010013
Received: 17 November 2012; in revised form: 17 December 2012 / Accepted: 4 January 2013 / Published: 14 January 2013| PDF Full-text (1028 KB) | HTML Full-text | XML Full-text
Diagnostics 2013, 3(1), 68-83; doi:10.3390/diagnostics3010068
Received: 8 December 2012; in revised form: 31 December 2012 / Accepted: 15 January 2013 / Published: 16 January 2013| PDF Full-text (474 KB) | HTML Full-text | XML Full-text
Diagnostics 2013, 3(1), 84-104; doi:10.3390/diagnostics3010084
Received: 15 November 2012; in revised form: 28 December 2012 / Accepted: 14 January 2013 / Published: 16 January 2013| Cited by 1 | PDF Full-text (715 KB) | HTML Full-text | XML Full-text
Diagnostics 2013, 3(1), 170-191; doi:10.3390/diagnostics3010170
Received: 5 February 2013; in revised form: 1 March 2013 / Accepted: 11 March 2013 / Published: 15 March 2013| Cited by 1 | PDF Full-text (213 KB) | HTML Full-text | XML Full-text
Last update: 25 February 2014